Natera, Inc.(NTRA) - Stock detail

Natera, Inc.

US
NTRA
Natera, Inc.(Listing date: 07/02/2015)

Natera, Inc. was incorporated in Delaware in January 2007. The company is a diagnostic company with proprietary molecular and bioinformatics technologies that it is applying to transform disease management worldwide. The company's cell-free DNA (cfDNA) technology combines novel molecular analytical methods that can reliably measure many informative regions across the entire genome from samples as small as a single cell, as well as statistical algorithms that incorporate data provided by the broader scientific community to identify genetic variations covering a wide range of serious diseases with high precision and high coverage. The company's goal is to make personalized genetic testing and diagnosis part of the standard of care for protecting health and inform earlier and more targeted interventions to help achieve longer, healthier lives.

AI Trading DecisionSell
Generated at:2026-05-07 17:47:16
Analysis data includes valuation metrics (P/S ratio 13.61, P/B ratio 25.42), financial data (2025 net loss $208M vs 2024 $190M, revenue growth 35.9% YoY, gross margin 64.75%), technical indicators (price $219.82, Bollinger Bands, RSI-6 66.75, Williams %R -4.63, KDJ J-line 89.95, ADX 7.33), and market sentiment data (85.94% of recent traders in profit, cost-concentration range $150.87–$216.80). Data time range includes recent price action and historical financial comparisons.
Summary

Trading strategy overview: Target price is $195.00 (US Dollar), stop-loss price is $206.00 (US Dollar), confidence level is 0.75, risk score is 0.65.

Operation strategy
  • Existing holders should sell into strength
  • Tighten stop-loss orders below $206 to protect gains
  • Potential buyers should avoid new positions until a pullback to $195–$200 with signs of stabilization
  • Monitor quarterly earnings reports for evidence of narrowing losses
  • Watch for any deterioration in revenue growth or gross margins

Core Support

Reasoning summary
  • Valuation unsustainability: NTRA trades at extreme multiples (P/S 13.61, P/B 25.42) with widening net losses, leaving no margin of safety
  • Technical overextension: Stock closed above upper Bollinger Band with short-term oscillators signaling extreme overbought conditions
  • Low ADX (7.33) indicates weak underlying trend strength, suggesting recent surge is a volatile spike
  • Sentiment exhaustion: Positive catalysts are 1–2 weeks old and likely already priced in
  • 85.94% of recent traders in profit creates heavy profit-taking pressure
  • Fundamental risk: Persistent and widening net losses reflect high operating expenses and unproven profitability
  • Company's path to breakeven remains uncertain, making premium valuation vulnerable to compression
  • Target price justification: Support levels at $206–$208 and $193.03
  • Valuation reset: Conservative P/S multiple of ~10x implies downward adjustment toward $200
  • Mean reversion suggests high probability of pullback to $195–$200 within 1–3 months